GlassScriptPhysician profile
Jesse Alan Hays
NPI 1851946545
$2,309.29
in general payments reported to CMS, 2019-2025
25 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $605 · 2023: $365 · 2024: $443 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $356.97 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.58 | 2021-2025 | |
| Amgen INC. | $220.26 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $211.19 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $112.98 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.30 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $99.86 | 2021-2023 | Mounjaro |
| Pfizer INC. | $65.43 | 2021-2025 | |
| Esperion Therapeutics, INC. | $55.89 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $53.86 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $53.76 | 2022-2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $44.90 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $42.81 | 2021-2022 | |
| Globus Medical, INC. | $31.09 | 2025 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.15 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.91 | 2022-2023 | Xarelto |
| Dexcom, INC. | $29.00 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $25.40 | 2023 | Gemtesa |
| Daiichi Sankyo INC. | $24.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2021 | |
| Exact Sciences Corporation | $16.65 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $15.11 | 2025 | |
| Abiomed | $14.79 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.